OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic: (OSE:DIAG) Presentation of results for fourth quarter 2012 will take place on Friday 15 February 2013, and not on Wednesday 27 February 2013 as per earlier announcement.
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com
This information was brought to you by Cision http://www.cisionwire.com
Contacts
DiaGenic ASA
Paul de Potocki, Chief Executive Officer
Telephone: 47 2324 8950
e-mail: paul.depotocki@diagenic.com
